Laboratoires Pierre Fabre has entered into a research collaboration with XtalPi Holdings Limited to identify and develop novel small-molecule drug candidates, initially targeting oncology indications. The partnership may expand into dermatology and rare diseases.
Under the agreement, XtalPi will utilize its artificial intelligence (AI) capabilities and robotics platform to design new small-molecule therapeutics against a series of undisclosed biological targets. Pierre Fabre will contribute its expertise in disease biology, drug discovery, translational research, and clinical development, taking responsibility for selecting promising candidates and advancing them through subsequent clinical and commercial development.
The collaboration will focus on targets that have historically presented challenges for drug discovery. By combining computational drug design and automated research capabilities with established pharmaceutical development expertise, the companies aim to improve the identification of potential clinical candidates across multiple research programs.
The financial terms include an upfront payment, milestone payments tied to development progress, and additional downstream economic participation. The specific value of the agreement was not disclosed.
Source: drug-dev.com · Image: IPA Restaurant by Postkarte, Public domain, via Wikimedia Commons
Open the full market picture for your next decision →
